While the drugs have already skyrocketed in popularity, specifically for people struggling to shed weight, huge cost savings with generics are expected to lower the barrier even more
adults lacked insurance coverage for GLP-1 medications, leaving many to bear substantial out-of-pocket costs (Long, 2024)
Over 30 brands were launched soon after patent expiry by several companies, including Dr Reddys Laboratories, Sun Pharma, Torrent Pharma, Glenmark, Eris Lifesciences, Zydus Lifesciences and more
Used appropriately
Chronic scalp inflammation is increasingly recognised as a contributing factor to hair loss, particularly in conditions like folliculitis and inflammatory alopecia
lower salivary cortisol, amylase, blood pressure, and subjective stress ratings (Lopresti 2022)